



ASX ANNOUNCEMENT

Change of Registered Office and Principal Place of Business Address

Perth, Australia; 25 September 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB ("NeuroScientific" or "the Company") wishes to advise, in accordance with ASX Listing Rule 3.14, that as of immediate effect its registered office and principal place of business will change to:

Suite 5, 85 Forrest Street
Cottesloe WA 6001

The Company's contact numbers remain the same.

About NeuroScientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

END

Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Non-executive Chairman
bl@neuroscientific.com
+61 412 281 780